PSAwatch developments in the UK and France

This was from the 8 December 2011 but forgot to update here:

PSAwatch developments in the UK and France

RNS Number : 5950T

Mediwatch PLC

08 December 2011

Mediwatch (AIM:MDW) is pleased to announce that PSAwatch continues to make good progress in line with the company strategy. Since moving to a new manufacturing site and obtaining a stable supply of test strips, Mediwatch has actively promoted PSAwatch in the UK and international markets.

In the UK charitable groups are switching to using PSAwatch as a PSA measuring device in well-man prostate awareness meetings. Mediwatch has been working closely with the Graham Fulford Charitable Trust (GFCT) for a number of years and they have transitioned to using PSAwatch as their standard method of PSA testing. Over the past few years, the GFCT (www.grahamfulford.org.uk) has raised over £275,000 and conducted over 20,000 free PSA tests across the UK, leading to the early diagnosis of nearly 500 prostate cancers to date.

In France, a clinical study which involved testing over 200 men has been carried out over the course of 2011 comparing PSAwatch to laboratory PSA values. The study, which was led by one of France's leading urologists, has been conducted at six locations across the country and five sites have now completed with the remaining hospital expected to finish patient testing before the end of 2011.

Based on the results from the first five sites, AVF Biomédical (SAS), Mediwatch's distributor in France, has launched the PSAwatch system at the Annual French Urology (AFU) congress in Paris which was held between 16^th and 19^th November 2011and they have already received orders. It is estimated that around 6 million PSA tests are conducted in France each year, for assisting both diagnosis and surveillance of prostate disease.

Mediwatch has begun direct marketing of PSAwatch into Europe, Middle East, Asia Pacific and Latin America. A large clinical trial is scheduled to begin at the Royal Hospital in Melbourne in Australia in early 2012. In addition, Mediwatch are looking into increasing the utility of the reader into other applications. These are very positive developments for the product line which management expects will see increasing revenues and exposure.

Enquiries

Mediwatch plc

Tel: +44 (0)1788 547 888

Philip Stimpson, Chief Executive

Fairfax I.S. PLC

Tel: +44 (0)20 7598 5368

Ewan Leggat / Laura Littley

Editors Notes:

Mediwatch plc: Innovative Diagnostic Solutions

Mediwatch is a leader in its field. The Company is continually striving to develop and market faster, simpler and less invasive diagnostic products to save lives and restore quality of life for people with a variety of urological conditions. Founded in 1995, Mediwatch (http://www.mediwatch.com) has developed a range of point-of-care medical equipment for the diagnosis of urological disorders.

The business focuses its design skills towards diagnostic products that can be used across the medical profession.

Mediwatch has established excellent foundations for continued growth building on the acquisition and integration of a division of Medtronic Inc in 2006, an international distribution network and its research and development programmes.

This information is provided by RNS

The company news service from the London Stock Exchange